Identification of a broad-spectrum azasordarin with improved pharmacokinetic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 8, 2003, Pages 1419-1423

  Serrano Wu, Michael H ^a   St Laurent, Denis R ^a   Carroll, Tina M ^a   Dodier, Marco ^a   Gao, Qi ^a   Gill, Patrice ^a   Quesnelle, Claude ^a   Marinier, Anne ^a   Mazzucco, Charles E ^a   Regueiro Ren, Alicia ^a   Stickle, Terry M ^a   Wu, Dedong ^a   Yang, Hyekyung ^a   Yang, Zheng ^a   Zheng, Ming ^a   Zoeckler, Mary E ^a   Vyas, Dolatrai M ^a   Balasubramanian, Balu N ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AZASORDARIN; SORDARIN; SORDARIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGAL STRAIN; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMA HALF LIFE;

ASPERGILLUS;

EID: 0037451848     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00161-6     Document Type: Article

References (24)

1. Stevens D.A., Holmberg K. Current Opin. in Anti-infective Invest. Drugs. 1:1999;306.
2. Hauser D., Sigg H.P. Helvetica Chim Acta. 54:1971;1178.
3. (a) Dominguez J.M., Martin J. J. Antimicrob. Agents Chemotherapy. 42:1998;2274
4. (b) Capa L., Mendoza A., Lavandra J.L., Gomez de Las H.F., Garcia-Bustos J.F. Antimicrob. Agents Chemotherapy. 42:1998;2279
5. (c) Justice M.C., Hsu M.J., Tse B., Ku T., Balkovec J., Schmatz D., Nielsen J. J. Biol. Chem. 273:1998;3148.
6. (a) For reviews, see: Odds F.C. Exp. Opin. Ther. Pat. 11:2001;283
7. (b) Ziegelbauer K., Spaltmann F. Drugs Fut. 25:2000;63
8. (c) Gargolla-Viola D. Current Opin. in Anti-infective Invest. Drugs. 1:1999;297.
9. Dominguez J.M., Gomez-Lorenzo M.G., Martin J.J. J. Biol. Chem. 274:1999;22423.
10. Herreros E., Almela M.J., Lozano S., Gomez de las Heras F., Gargallo-Viola D. Antimicrob. Agents Chemother. 45:2001;3132.
11. (a)For other heterocyclic replacements of the tetrahydropyranyl sidechain, see: Kaneko S., Arai M., Uchida T., Harasaki T., Fukuoka T., Konosu T. Bioorg. Med. Chem. Lett. 12:2002;1705
12. (b) Serrano-Wu M.H., St. Laurent D.R., Chen Y., Huang S., Lam K., Matson J.A., Mazzucco C.E., Stickle T.M., Tully T.P., Wong H.S., Vyas D.M., Balasubramanian B.N. Bioorg. Med. Chem. Lett. 12:2002;2757
13. (c) Arai M., Harasaki T., Fukuoka T., Kaneko S., Konosu T. Bioorg. Med. Chem. Lett. 12:2002;2733.
14. Aviles, P.; Pateman, A.; San Roman, R.; Guillen, M.; Gargolla-Viola, D. 40th Meeting of the Intersciences Conference of Antimicrobial Agents and Chemotherapy (2000), Abstract 1690.
15. (a) Amino alcohols were commercially available or prepared from the corresponding epoxide. For example, see: Schaus S.E., Larrow J.F., Jacobsen E.N. J. Org. Chem. 62:1997;4197
16. (b) Katagiri T., Takahashi M., Fujiwara Y., Ihara H., Uneyama K. J. Org. Chem. 64:1999;7323.
17. (a) Coteron J.M., Chiara J.L., Fernandez-Mayoralas A., Fiandor J.M., Valle N. Tetrahedron Lett. 41:2000;4373
18. (b) Bueno J.M., Chicharro Gonzalo J., Coteron J., Cuevas J.C., Fiandor J.M., Mallo A.; WO 9958512; Chem. Abstr. 131:1999;337207.
19. The greater nucleophilicity of β-alkoxide pyranose anions has been elegantly demonstrated by Schmidt; see: Schmidt R. Angew. Chem., Int. Ed. Engl. 25:1986;212. We are grateful to a referee for bringing this reference to our attention.
20. +): 534.2986; found 534.2987.
21. (a) The exceptional MIC observed with several analogues versus C. neoformans and Asp. fumigatus is interesting in light of recent studies which suggest that EF-2 in these fungi should not be susceptible to sordarin derivatives. See: Shastry M., Nielsen J., Ku T., Hsu M., Liberator P., Anderson J., Schmatz D., Justice M.C. Microbiology. 147:2001;383
22. (b) Santos C., Ballesta J.P.G. Molec. Microb. 43:2002;227.
23. The anomeric configuration of 7g was established by X-ray crystallography of the corresponding morpholine precursor 6. The α-anomer of compound 7g was considerably less active against all pathogens tested (C. albicans MIC=0.5 μg/mL; C. glabrata MIC=4 μg/mL; all others > 16 μg/mL).
24. Although 7a exhibited high total body clearance after iv administration, the oral bioavailability was 100%, which may be attributed to the rapid absorption of 7a and the resulting saturation of first-pass liver metabolism.